Stock listing

BOATS:IMRX Immuneering Corporation Stock

US listing (BOATS) of Immuneering Corporation · home listing NASDAQ:IMRX

Follow Immuneering Corporation into a list and get an email when it puts out news.

Home listing price · NASDAQ:IMRX

$3.38 USD -0.12 (-3.4%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:IMRX

Past year -51.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.29 – $3.54 USDNov 20, 2026
Volume
1.45M sharesNov 20, 2026
Market cap
$218.7M USDAt the close on Nov 20, 2026 · price × 64.70M shares outstanding
52-week range
$3.29 – $8.48 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$3.02M USDMedian day 709,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Immuneering Corporation logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IMRX · Home$3.38 USD-0.12 (-3.4%)1,453,421$3.38$3.541$3.289$3.50Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IMRX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.38-0.12-3.4%$3.38$3.541$3.2891,453,421
$3.50+0.04+1.2%$3.46$3.575$3.43730,703
$3.46-0.06-1.7%$3.58$3.63$3.3151,247,741
$3.52-0.19-5.1%$3.70$3.78$3.4751,019,933
$3.71+0.04+1.1%$3.71$3.746$3.545847,339
$3.67-0.12-3.2%$3.86$3.885$3.65476,835
$3.79-0.06-1.6%$3.89$3.95$3.79455,755
$3.85+0.20+5.5%$3.66$3.895$3.65769,411
$3.65-0.03-0.8%$3.69$3.725$3.54849,101
$3.68+0.31+9.2%$3.41$3.695$3.368681,434
$3.37-0.39-10.4%$3.74$3.74$3.35761,851
$3.76+0.08+2.2%$3.74$3.87$3.70730,404
$3.68+0.19+5.4%$3.52$3.76$3.52877,867
$3.49-0.255-6.8%$3.76$3.94$3.445799,866
$3.745-0.275-6.8%$4.01$4.07$3.721,138,655
$4.02+0.03+0.8%$3.99$4.10$3.875770,876
$3.99+0.16+4.2%$3.80$4.155$3.791,442,484
$3.83+0.12+3.2%$3.72$3.888$3.70699,488
$3.71-0.02-0.5%$3.73$3.775$3.66579,759
$3.73-0.08-2.1%$3.78$3.78$3.585726,538
$3.81+0.07+1.9%$3.72$3.835$3.70527,134
$3.74+0.01+0.3%$3.73$3.80$3.68481,881
$3.73+0.07+1.9%$3.70$3.841$3.67926,844
$3.66+0.07+1.9%$3.61$3.67$3.56427,112
$3.59-0.05-1.4%$3.65$3.68$3.575747,900
$3.64+0.22+6.4%$3.42$3.71$3.38934,300
$3.42-0.14-3.9%$3.51$3.598$3.41803,700
$3.56-0.30-7.8%$3.86$3.86$3.545734,400
$3.86-0.08-2.0%$3.94$3.945$3.814529,700
$3.94+0.20+5.3%$3.75$3.955$3.68709,700
$3.74-0.12-3.1%$3.83$3.83$3.601,922,000
$3.86+0.03+0.8%$3.78$3.915$3.74747,700
$3.83-0.21-5.2%$4.06$4.09$3.81898,400
$4.04-0.03-0.7%$4.07$4.12$4.02479,700
$4.07+0.04+1.0%$4.10$4.145$4.02588,800
$4.03-0.065-1.6%$4.10$4.17$4.01538,200
$4.095-0.035-0.8%$4.16$4.23$4.09596,800
$4.13-0.03-0.7%$4.16$4.16$4.065574,400
$4.16-0.11-2.6%$4.25$4.25$4.125597,900
$4.27-0.07-1.6%$4.36$4.40$4.255513,400
$4.34-0.04-0.9%$4.36$4.38$4.20589,600
$4.38-0.23-5.0%$4.62$4.65$4.355551,500
$4.61+0.17+3.8%$4.50$4.665$4.45590,400
$4.44-0.04-0.9%$4.55$4.57$4.38540,300
$4.48+0.02+0.4%$4.46$4.52$4.4151,077,900
$4.46+0.01+0.2%$4.55$4.55$4.405576,100
$4.45+0.01+0.2%$4.45$4.505$4.398899,800
$4.44+0.11+2.5%$4.33$4.475$4.24862,100
$4.33+0.06+1.4%$4.28$4.435$4.26493,800
$4.27-0.30-6.6%$4.63$4.65$4.24901,400
$4.57-0.04-0.9%$4.53$4.685$4.47624,000
$4.61-0.17-3.6%$4.74$4.81$4.541,165,700
$4.78-0.04-0.8%$4.82$4.885$4.6851,043,900
$4.82-0.22-4.4%$4.94$5.00$4.805999,900
$5.04+0.02+0.4%$5.085$5.105$4.93424,400
$5.02+0.17+3.5%$4.85$5.055$4.80678,600
$4.85-0.14-2.8%$4.90$4.985$4.84435,000
$4.990.000.0%$5.00$5.01$4.863587,400
$4.99-0.22-4.2%$5.21$5.214$4.935793,700
$5.21+0.06+1.2%$5.19$5.395$5.12787,700
$5.15-0.08-1.5%$5.23$5.23$5.109460,000
$5.23+0.05+1.0%$5.20$5.38$5.20364,300
$5.18-0.12-2.3%$5.31$5.35$5.125400,571
$5.30+0.05+1.0%$5.31$5.43$5.281443,600
$5.25-0.08-1.5%$5.25$5.37$5.20473,200
Ticker
BOATS:IMRX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BOATS
Currency
USD

What changed lately

Latest news

All Immuneering Corporation news

Immuneering Corporation on 6ix

Sector
Health care
Industry
Biotechnology
News releases
36 in the last 12 months · 107 in all · newest Nov 18, 2026 · oldest 2021
Calls
2 calls with a replay · 2 with a transcript · latest Nov 12, 2025
Decks
5 decks · latest September 2026

Where Immuneering Corporation is listed

ListingExchangeCountryCurrency
NASDAQ:IMRX · Home listingNASDAQUnited StatesUSD
BOATS:IMRX · This pageBOATSUnited StatesUSD

Valuation

Price/book 1.3× against a median of 1.6×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$160.5M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.17

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Immuneering Corporation · NASDAQ:IMRXUS$218.7MUS$160.5Mn/an/an/a1.3×n/a0.0×1.17
Enanta Pharmaceuticals, Inc. · NASDAQ:ENTAUS$222.2MUS$82.43Mn/a1.3×n/a2.8×−108.3%0.7×1.11
Clover Biopharmaceuticals Ltd. · HKEX:2197US$222.0MUS$206.5Mn/a403×n/an/an/an/an/a
Aprilbio Co., Ltd. · KRX:397030US$221.1MUS$161.1Mn/an/an/a3.1×n/a0.0×n/a
Northwest Biotherapeutics, Inc. · OTC:NWBOUS$220.0MUS$283.8Mn/a99.4×n/an/an/an/a0.90
Keros Therapeutics, Inc. · NASDAQ:KROSUS$219.7M−US$24.67Mn/a−0.6×n/a0.8×−152.7%0.1×1.16
Allogene Therapeutics, Inc. · NASDAQ:ALLOUS$217.5M−US$7.44Mn/a−1.6×n/a0.6×n/a0.2×1.93
ProKidney Corp. · NASDAQ:PROKUS$217.3MUS$77.56Mn/a100×n/an/an/an/a1.61
Pyxis Oncology, Inc. · NASDAQ:PYXSUS$216.5MUS$160.9Mn/an/an/a5.2×n/a0.0×0.89
Oryzon Genomics SA · BME:ORYUS$216.4MUS$206.7Mn/an/an/a1.6×n/a0.1×n/a
Rocket Pharmaceuticals, Inc. · NASDAQ:RCKTUS$214.1M−US$25.02Mn/an/an/a0.7×n/a0.1×1.72
Median of the othersUS$218.6MUS$121.7M50.3×1.6×−130.5%0.1×1.16

Forecasts

5 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
17.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.26 · 7 analysts

Team and board

Officers

OfficerRole
Ben ZeskindCo-Founder, President, Chief Executive Officer, Director
Andrew GengosChief Financial Officer and Treasurer
Dominic CapassoAssociate General Counsel
Michael BookmanChief Legal Officer, Secretary
David CaouetteVice President, Corporate Communications
Jason FuntVice President, Translational Genomics
Kevin D. FowlerVice President, Translational Research
Loretta SullivanVice President, Medical Affairs and Scientific Development
Mallory MoralesSVP Finance, Chief Accounting Officer, and Assistant Treasurer
Nair PraveenVice President, Head of Translational Pharmacology
Vinny HayrehVice President, Clinical Development
Anna TravesaExecutive Director, Discovery
Bob CarpenterCo-founder, Chair Emeritus
Brett HallChief Scientific Officer
Doris Perez DiazClinical Trial Manager
Igor MatushanskyChief Medical Officer
Marty HughesExecutive Director, CMC
Paula GeorgeSenior Director, Accounting & Operations; Assistant Corporate Controller
Scott NguyenExecutive Director, IT
Stephen SebastianExecutive Director, Corporate Controller
Tyler MeadSenior Manager, Financial Reporting and Internal Controls
Zhang JennyExecutive Director, Genomic Data Science

Board

DirectorRole
Bob CarpenterCo-founder, Chair Emeritus
Tom SchallBoard Chair
Anna TravesaExecutive Director, Discovery
Ben ZeskindCo-Founder, President, Chief Executive Officer, Director
Diana HausmanBoard Member
Grant BogleBoard Member
Laurie KeatingBoard Member
Marty HughesExecutive Director, CMC
Peter FeinbergBoard Member
Scott NguyenExecutive Director, IT
Stephen SebastianExecutive Director, Corporate Controller
Zhang JennyExecutive Director, Genomic Data Science

Events

Calls

CallWhenStatus
Immuneering (NASDAQ:IMRX) Q3 2025 Earnings CallWed, Nov 12, 2025 · 4:30 PM ETReplay
Immuneering (NASDAQ:IMRX) Q4 2022 Earnings CallMon, Mar 06, 2023 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Oct 29, 2026 · After close−6.8%
Q2 2026Aug 5, 2026 · Before open−0.2%
Q1 2026May 12, 2026+3.5%
Q4 2025Mar 6, 2026 · Before open+7.0%
Q3 2025Nov 12, 2025 · After close−2.6%
Q2 2025Aug 13, 2025 · After close−5.6%
Q1 2025May 5, 2025 · After close−4.8%
Q4 2024Mar 20, 2025+7.1%
Q3 2024Nov 13, 2024 · After close+13.4%
Q2 2024Aug 6, 2024 · After close−8.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · After close+4.5%
Q4 2023Mar 1, 2024 · Before open−0.8%
Q3 2023Nov 9, 2023 · After close−0.3%
Q2 2023Aug 3, 2023 · After close+1.9%
Q1 2023May 4, 2023 · After close−0.6%
Q4 2022Mar 6, 2023 · After close+6.2%
Q3 2022Nov 10, 2022 · Before open0.0%
Q2 2022Aug 10, 2022 · After close−5.0%
Q1 2022May 10, 2022 · Before open+14.0%
Q4 2021Mar 10, 2022 · Before open−0.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck28 slidesSeptember 2026
Investor Presentation (November 2025)Investor deck30 slidesNovember 2025
Investor Presentation (September 2025)Investor deck27 slidesSeptember 2025
Investor Presentation (April 2023)Investor deck47 slidesApr 18, 2023
Investor Presentation (March 2023)Investor deck39 slidesMar 6, 2023

Open Decks

Financings

RaiseDate
Public offering of class A common stock or pre-funded warrants
Announced: Leerink Partners +1
Dealers: Leerink Partners (co-lead), Oppenheimer & Co. Inc. (co-lead)
Use of proceeds: Advance preclinical and clinical development of product candidates, working capital and general corporate purposes
Sep 24, 2025
Private placement of class A common stock or non-voting Class B common stock
Announced: US$25M · Leerink Partners +1
Dealers: Leerink Partners, Oppenheimer & Co. Inc.
Buyers: Sanofi ($25.0 million of Class A common stock or non-voting Class B common stock)
Use of proceeds: Advance preclinical and clinical development of product candidates, working capital and general corporate purposes
Sep 24, 2025
Private placement of class A common stock (or pre-funded warrants) and accompanying purchase warrants
Closed: US$25M raised · US$3.95 a share · Warrants at US$5.5 for 60 months · Leerink Partners
Dealers: Leerink Partners
Use of proceeds: Support development of atebimetinib, its Deep Cyclic Inhibitor of MEK, for cancer patients
Aug 26, 2025
At-the-market programme of common stock
Closed: US$13.7M raised
Jan 13, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$15.00 a share on Jul 29, 2021.

Price
US$15.00 a share
Shares offered
7,500,000 shares of Class A common stock
Offering size
US$112.5 million
Underwriters' option
Up to 1,125,000 more shares
Listing
IMRX on the Nasdaq Global Market
Underwriters
MORGAN STANLEY, JEFFERIES, COWEN, GUGGENHEIM SECURITIES · In the order on the cover
Shares delivered
On or about Aug 3, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceMay 13, 2021
Filed publiclyJul 9, 2021
Amended twiceNewest Jul 28, 2021
Shares registered with an exchangeJul 27, 2021
Declared effective by the SECJul 29, 2021
Final prospectus, with the priceJul 30, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Jul 30, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue0317.0K2.08M2.31M
Cost of revenue0158.1K1.15M1.28M
Gross profit0158.8K926.9K1.03M
Research and development42.0M48.0M41.6M36.3M26.5M15.0M
Operating income-59.4M-64.1M-58.4M-51.7M-33.9M-17.1M
Depreciation and amortization324.5K355.8K322.8K247.2K45.5K24.3K
EBITDA-59.1M-63.7M-58.1M-51.5M-33.8M-17.1M
Income before tax-50.5M-33.8M-17.0M
Income tax0-307.5K
Net income-56.0M-61.0M-53.5M-50.5M-33.5M-17.0M
Earnings per share, basic-1.27-2.04-1.88-1.91-2.46-3.44
Earnings per share, diluted-1.27-2.04-1.88-1.91-2.46-3.44

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents128.6M36.1M59.4M72.6M74.9M37.1M
Short-term investments026.3M32.9M74.3M
Receivables012.4K246.0K500.1K
Current assets176.2M39.6M89.1M108.7M152.3M37.7M
Property, plant and equipment938.5K1.12M1.40M1.37M807.2K64.4K
Goodwill6.69M6.69M6.69M6.69M6.70M
Total assets232.0M52.7M102.6M122.4M166.7M38.4M
Accounts payable1.54M1.96M2.11M3.15M1.39M1.48M
Current liabilities10.1M7.50M7.85M8.05M5.63M2.26M
Total liabilities13.5M11.3M12.0M12.5M10.7M2.80M
Shareholders' equity218.5M41.4M90.6M109.9M156.0M-22.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-45.3M-55.0M-49.0M-44.1M-30.9M-14.6M
Capital spending-142.2K-84.9K-342.7K-742.5K-60.8K-53.4K
Free cash flow-45.5M-55.1M-49.3M-44.8M-30.9M-14.7M
Cash from investing-88.7M26.4M7.30M41.8M-75.6M-53.4K
Cash from financing226.6M5.30M28.4M19.0K144.3M38.0M
Change in cash92.5M-23.3M-13.2M-2.25M37.8M23.3M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 9, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 9, 2026Insider tradeSEC
8-K · Current reportNov 9, 2026Management or board changeSEC
10-Q · Quarterly reportOct 29, 2026Quarterly reportSEC
8-K · Current reportOct 29, 2026ResultsSEC
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
8-K · Current reportAug 5, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 28, 2026Big-stake noticeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
3 · Initial statement of ownershipJul 16, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
8-K · Current reportJun 15, 2026Management or board changeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
8-K · Current reportJun 11, 2026Meeting outcomeSEC
8-K · Current reportJun 1, 2026Current reportSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
8-K · Current reportMay 15, 2026ResultsSEC
DEFA14A · Additional proxy materialApr 20, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 20, 2026Meeting noticeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
10-K · Annual reportMar 6, 2026Annual reportSEC
8-K · Current reportMar 6, 2026ResultsSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 22, 2026Big-stake noticeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 15, 2026Big-stake noticeSEC
4 · Change in ownershipJan 15, 2026Insider tradeSEC
4 · Change in ownershipJan 14, 2026Insider tradeSEC
8-K · Current reportJan 7, 2026Current reportSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 21, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 7, 2025Big-stake noticeSEC
4 · Change in ownershipOct 7, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 3, 2025Big-stake noticeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipOct 1, 2025Insider tradeSEC
4 · Change in ownershipSep 30, 2025Insider tradeSEC
424B5 · ProspectusSep 25, 2025Offer documentSEC
8-K · Current reportSep 25, 2025Material contractSEC
FWP · Free writing prospectusSep 25, 2025Offer documentSEC
FWP · Free writing prospectusSep 24, 2025Offer documentSEC
424B5 · ProspectusSep 24, 2025Offer documentSEC
8-K · Current reportSep 24, 2025Material contractSEC
144 · Notice of proposed saleSep 23, 2025Other filingsSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
DSep 9, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveSep 9, 2025Other filingsSEC
424B3 · ProspectusSep 8, 2025Offer documentSEC
CORRESP · Letter to the SECSep 4, 2025Other filingsSEC
UPLOAD · Letter from the SECSep 4, 2025Other filingsSEC
S-3 · Registration statementSep 2, 2025Offer documentSEC
8-K · Current reportAug 22, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveAug 21, 2025Other filingsSEC
CORRESP · Letter to the SECAug 18, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 18, 2025Other filingsSEC
S-3 · Registration statementAug 13, 2025Offer documentSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 13, 2025ResultsSEC
4 · Change in ownershipJul 7, 2025Insider tradeSEC
4 · Change in ownershipJul 7, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
424B5 · ProspectusJun 23, 2025Offer documentSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
8-K · Current reportJun 17, 2025Current reportSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
8-K · Current reportJun 16, 2025Meeting outcomeSEC
10-Q · Quarterly reportMay 5, 2025Quarterly reportSEC
8-K · Current reportMay 5, 2025ResultsSEC
S-8 · Registration statement for employee plansMay 5, 2025Offer documentSEC
DEFA14A · Additional proxy materialApr 21, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 21, 2025Meeting noticeSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 24, 2025Insider tradeSEC
424B5 · ProspectusMar 20, 2025Offer documentSEC
10-K · Annual reportMar 20, 2025Annual reportSEC
8-K · Current reportMar 20, 2025ResultsSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 17, 2025Big-stake noticeSEC
8-K · Current reportJan 13, 2025Current reportSEC
8-K · Current reportJan 7, 2025Current reportSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
8-K/A · Current report, amendedOct 2, 2024Management or board changeSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
8-K · Current reportSep 12, 2024Current reportSEC
10-Q · Quarterly reportAug 6, 2024Quarterly reportSEC
8-K · Current reportAug 6, 2024ResultsSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
8-K · Current reportJun 13, 2024Meeting outcomeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
8-K · Current reportMay 23, 2024Management or board changeSEC
10-Q · Quarterly reportMay 7, 2024Quarterly reportSEC
8-K · Current reportMay 7, 2024ResultsSEC
DEFA14A · Additional proxy materialApr 23, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2024Meeting noticeSEC
SC 13G/A · Big-stake notice, amendedApr 15, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedApr 10, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedApr 5, 2024Big-stake noticeSEC
4 · Change in ownershipApr 3, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedMar 27, 2024Big-stake noticeSEC
4 · Change in ownershipMar 25, 2024Insider tradeSEC
4 · Change in ownershipMar 25, 2024Insider tradeSEC
4 · Change in ownershipMar 25, 2024Insider tradeSEC
4 · Change in ownershipMar 25, 2024Insider tradeSEC
4 · Change in ownershipMar 21, 2024Insider tradeSEC
4 · Change in ownershipMar 21, 2024Insider tradeSEC
4 · Change in ownershipMar 19, 2024Insider tradeSEC
4 · Change in ownershipMar 19, 2024Insider tradeSEC
4 · Change in ownershipMar 19, 2024Insider tradeSEC
4 · Change in ownershipMar 19, 2024Insider tradeSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
8-K · Current reportMar 14, 2024Management or board changeSEC
4 · Change in ownershipMar 12, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 12, 2024Insider tradeSEC
10-K · Annual reportMar 1, 2024Annual reportSEC
8-K · Current reportMar 1, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
8-K · Current reportFeb 2, 2024Current reportSEC
SC 13G · Big-stake noticeJan 26, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 16, 2024Big-stake noticeSEC
4 · Change in ownershipJan 2, 2024Insider tradeSEC
4 · Change in ownershipJan 2, 2024Insider tradeSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
10-Q · Quarterly reportAug 3, 2023Quarterly reportSEC
8-K · Current reportAug 3, 2023ResultsSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
8-K · Current reportJun 15, 2023Meeting outcomeSEC
4 · Change in ownershipJun 14, 2023Insider tradeSEC
8-K · Current reportJun 14, 2023Management or board changeSEC
SC 13G/A · Big-stake notice, amendedMay 5, 2023Big-stake noticeSEC
10-Q · Quarterly reportMay 4, 2023Quarterly reportSEC
8-K · Current reportMay 4, 2023Current reportSEC
DEFA14A · Additional proxy materialMay 1, 2023Meeting noticeSEC
DEF 14A · Proxy statementMay 1, 2023Meeting noticeSEC
SC 13G/A · Big-stake notice, amendedApr 24, 2023Big-stake noticeSEC
3 · Initial statement of ownershipApr 24, 2023Insider tradeSEC
8-K · Current reportApr 19, 2023Material contractSEC
424B5 · ProspectusApr 19, 2023Offer documentSEC
424B5 · ProspectusApr 18, 2023Offer documentSEC

This page holds 200 of 326 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Immuneering Corporation’s releases · as of Sep 24, 2025

Common shares
64,697,402
Fully diluted
64,697,402

Fully diluted

LineShares
Common shares64,697,402

Warrants and options

Lot
Warrants · US$5.50 · expire about Aug 2030

Share count over time

CountShares
Nov 22, 202664,697,402

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Fidelity9.19M14.2%US$37.6MSep 30, 2026
BlackRock4.87M7.5%US$19.9MSep 30, 2026
Vanguard3.07M4.7%US$12.6MSep 30, 2026
Sanofi2.71M4.2%US$11.1MSep 30, 2026
Geode Capital1.37M2.1%US$5.63MSep 30, 2026
T. Rowe Price1.24M1.9%US$5.06MSep 30, 2026
State Street1.15M1.8%US$4.72MSep 30, 2026
Nuveen869K1.3%US$3.56MSep 30, 2026
DCF Advisers, LLC863K1.3%US$3.53MSep 30, 2026
abrdn785K1.2%US$3.21MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Marshall Wace, LLP734K1.1%US$3MSep 30, 2026
Goldman Sachs607K0.94%US$2.49MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.580K0.90%US$2.38MSep 30, 2026
Summit Financial, LLC474K0.73%US$1.94MSep 30, 2026
Alethea Capital Management, LLC473K0.73%US$1.94MSep 30, 2026
Northern Trust443K0.69%US$1.82MSep 30, 2026
Gendell Jeffrey L388K0.60%US$1.59MSep 30, 2026
UBS351K0.54%US$1.44MSep 30, 2026
Occam Crest Management LP325K0.50%US$1.33MSep 30, 2026
Morgan Stanley314K0.48%US$1.28MSep 30, 2026
Burkehill Global Management, LP300K0.46%US$1.23MSep 30, 2026
Levin Capital Strategies, L.P.212K0.33%US$868KSep 30, 2026
Pvg Asset Management Corp186K0.29%US$761KSep 30, 2026
Schwab176K0.27%US$722KSep 30, 2026
HighTower Advisors, LLC150K0.23%US$615KSep 30, 2026
Prosight Management, LP150K0.23%US$614KSep 30, 2026
BNY139K0.22%US$570KSep 30, 2026
Kingsview Wealth Management, LLC123K0.19%US$504KSep 30, 2026
Fisher Asset Management, LLC116K0.18%US$475KSep 30, 2026
Envestnet Asset Management Inc108K0.17%US$440KSep 30, 2026
Gsa Capital Partners LLP101K0.16%US$415KSep 30, 2026
Bank of America92,4330.14%US$379KSep 30, 2026
Citadel89,8950.14%US$368KSep 30, 2026
Alps Advisors Inc85,1090.13%US$349KSep 30, 2026
Bridgeway Capital Management, LLC82,0570.13%US$336KSep 30, 2026
Neuberger Berman Group LLC76,8410.12%US$315KSep 30, 2026
Empowered Funds, LLC73,7570.11%US$302KSep 30, 2026
Ameriprise71,5000.11%US$293KSep 30, 2026
Susquehanna69,8710.11%US$286KSep 30, 2026
American Century68,7510.11%US$282KSep 30, 2026
Two Sigma68,5450.11%US$281KSep 30, 2026
D. E. Shaw & Co., Inc.67,9200.10%US$278KSep 30, 2026
Hrt Financial LP66,6900.10%US$273KSep 30, 2026
Rhumbline Advisers66,0860.10%US$271KSep 30, 2026
Wealth Effects LLC65,3000.10%US$267KSep 30, 2026
Clearstead Advisors, LLC60,8650.09%US$249KSep 30, 2026
Flower City Capital60,0290.09%US$246KSep 30, 2026
Brandywine Managers, LLC55,0660.09%US$225KSep 30, 2026
WINTON GROUP Ltd47,9000.07%US$196KSep 30, 2026
XTX Topco Ltd47,8540.07%US$196KSep 30, 2026

This page holds 50 of 127 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Fidelity Growth Company Fund2.94M4.5%US$17MMay 31, 2026
Vanguard Total Stock Market Index Fund1.62M2.5%US$8.1MJun 30, 2026
iShares Russell 2000 ETF1.36M2.1%US$6.81MJun 30, 2026
Select Biotechnology Portfolio1.1M1.7%US$6.32MMay 31, 2026
T. Rowe Price New Horizons Fund, Inc.907K1.4%US$4.52MJun 30, 2026
Fidelity Growth Company K6 Fund828K1.3%US$4.78MMay 31, 2026
Fidelity Series Growth Company Fund720K1.1%US$4.15MMay 31, 2026
Vanguard Extended Market Index Fund612K0.95%US$3.06MJun 30, 2026
Fidelity Small Cap Index Fund584K0.90%US$2.41MJul 31, 2026
iShares Russell 2000 Value ETF497K0.77%US$2.48MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
T. Rowe Price Health Sciences Fund, Inc.388K0.60%US$1.93MJun 30, 2026
iShares Biotechnology ETF388K0.60%US$1.93MJun 30, 2026
Nuveen Equity Index Fund330K0.51%US$1.36MJul 31, 2026
Fidelity Extended Market Index Fund282K0.44%US$1.63MMay 31, 2026
iShares Micro-Cap ETF180K0.28%US$900KJun 30, 2026
Schwab Small-Cap Index Fund131K0.20%US$539KJul 31, 2026
Fidelity Total Market Index Fund103K0.16%US$595KMay 31, 2026
Master Small Cap Index Series100K0.15%US$500KJun 30, 2026
Fidelity Series Total Market Index Fund82,2910.13%US$475KMay 31, 2026
Large-Cap Growth Portfolio76,2190.12%US$380KJun 30, 2026
Fidelity Small Cap Value Index Fund74,9810.12%US$374KJun 30, 2026
Nuveen Small Cap Blend Index Fund71,4450.11%US$295KJul 31, 2026
EQ/2000 Managed Volatility Portfolio58,3690.09%US$291KJun 30, 2026
Avantis U.S. Small Cap Equity ETF52,2960.08%US$302KMay 31, 2026
Ultra-Small Company Fund50,0000.08%US$250KJun 30, 2026
Ultra-Small Company Market Fund49,8490.08%US$249KJun 30, 2026
Goldman Sachs Small Cap Equity Insights Fund45,9910.07%US$190KJul 31, 2026
Fidelity Nasdaq Composite Index Fund41,0050.06%US$237KMay 31, 2026
LVIP State Street Small-Cap Index Fund39,7000.06%US$198KJun 30, 2026
Schwab Total Stock Market Index Fund37,3440.06%US$154KJul 31, 2026
T. Rowe Price Health Sciences Portfolio35,8350.06%US$179KJun 30, 2026
Vanguard Balanced Index Fund29,5770.05%US$148KJun 30, 2026
Small Cap Index Fund27,7830.04%US$139KJun 30, 2026
Global X Russell 2000 ETF25,5250.04%US$105KJul 31, 2026
ATM Small Cap Managed Volatility Portfolio24,5020.04%US$122KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund20,9370.03%US$104KJun 30, 2026
EQ/Small Company Index Portfolio20,1100.03%US$100KJun 30, 2026
EQ/AB Small Cap Growth Portfolio20,1100.03%US$100KJun 30, 2026
MetLife Russell 2000 Index Portfolio18,9740.03%US$94,680Jun 30, 2026
College Retirement Equities Fund - Total Global Stock Account18,2600.03%US$91,117Jun 30, 2026
Small-Cap Index Portfolio15,4100.02%US$76,896Jun 30, 2026
Health Sciences Trust11,9950.02%US$59,855Jun 30, 2026
NVIT Small Cap Index Fund11,9930.02%US$59,845Jun 30, 2026
1290 VT Micro Cap Portfolio11,9620.02%US$59,690Jun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio11,7000.02%US$58,383Jun 30, 2026
Small Cap Index Trust11,1800.02%US$55,788Jun 30, 2026
Guardian Large Cap Fundamental Growth VIP Fund9,7220.02%US$48,513Jun 30, 2026
iShares Russell Small/Mid-Cap Index Fund9,5320.01%US$39,367Jul 31, 2026
EQ/T.Rowe Price Health Sciences Portfolio8,7670.01%US$43,747Jun 30, 2026
DWS Small Cap Index VIP8,4030.01%US$41,931Jun 30, 2026

This page holds 50 of 83 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Gengos Andrew
Officer: Chief Financial Officer
Buy25,000USD 3.58US$89,500Nov 13, 2026
Zeskind Benjamin J.
Director, Officer: PRESIDENT AND CEO
Buy2,400USD 4.56US$10,944Jun 23, 2026
Hall Brett Matthew
Officer: CHIEF SCIENTIFIC OFFICER
Buy6,035USD 4.15US$25,045Jun 15, 2026

Big stakes

StakeStakeSharesDateFiling
FMR LLC14.50%8.79MSep 30, 2025Schedule 13G
BlackRock, Inc.6.70%4.36MJun 30, 2026Schedule 13G
BENJAMIN J. ZESKIND6.60%4.36MDec 31, 2025Schedule 13G
HBM Healthcare Investments (Cayman) Ltd.5.70%3.65MSep 26, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Andrew Gengos
Other companies: Turn Therapeutics Inc. (Director · Since at least Oct 7, 2025); Terns Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Feb 24, 2025); LeonaBio, Inc. (CFO and Chief Business Officer · May 18, 2023 – Sep 3, 2024 · Past); Cyteir Therapeutics Inc (Chief Business Officer · Jun 17, 2021 – Feb 22, 2022 · Past); Synlogic Inc (Chief Operating Officer · Oct 9, 2017 – Mar 14, 2018 · Past)
Chief Financial Officer and Treasurer · Since at least Jul 16, 2026
Laurie Keating
Other companies: Kalaris Therapeutics, Inc. (Director · Since at least Jul 6, 2026); PepGen Inc. (Director · Since at least May 5, 2022); Imago Biosciences Inc (Director · Nov 17, 2021 – Jan 11, 2023 · Past); Alnylam Pharmaceuticals, Inc. (EVP, Chief Legal Officer · Jan 11, 2021 – Aug 5, 2021 · Past)
Director · Since at least Jul 29, 2021
Ann E Berman
Other companies: Loews Corporation (Director · Since at least Mar 1, 2021); Cantel Medical Corp (Director · Apr 5, 2021 – Jun 2, 2021 · Past); Eaton Vance Corp (Director · Nov 1, 2020 – Feb 12, 2021 · Past)
Director · Since at least Jul 29, 2021
Diana Hausman
Other companies: Zentalis Pharmaceuticals, Inc. (Chief Medical Officer · May 8, 2023 – May 9, 2024 · Past); Zymeworks Inc. (Chief Medical Officer · Jan 1, 2019 – Mar 10, 2021 · Past); Cascadian Therapeutics Inc (Chief Medical Officer · Mar 5, 2012 – Sep 24, 2015 · Past)
Board Member · Since at least Jan 14, 2022
Biren Amin
Other companies: Social Capital Suvretta Holdings Corp IV (Director · Jun 29, 2022 – Jun 29, 2022 · Past)
CFO, TREASURER · Jul 29, 2021 – May 12, 2022 · Past
Igor Matushansky
Other companies: Hookipa Pharma Inc (Chief Medical Officer · Apr 17, 2019 – Jun 30, 2022 · Past)
Chief Medical Officer · Since at least Mar 17, 2025
Michael Bookman
Other companies: Korro Bio, Inc. (General Counsel and Secretary · Jan 19, 2021 – Apr 20, 2021 · Past)
Chief Legal Officer, Secretary · Since at least Jul 29, 2021
Thomas J Schall
Other companies: ChemoCentryx Inc. (President and CEO, Director · Feb 8, 2012 – Oct 20, 2022 · Past)
Director · Since at least Mar 11, 2024
Amy AxelDirector, Scientific Operations · Oct 2, 2026 – Nov 10, 2026 · Past
Anna TravesaExecutive Director, Discovery · Since at least Nov 4, 2026
All 38 people
PersonSeat
Benjamin J ZeskindPRESIDENT AND CEO, Director · Since at least Jul 29, 2021
Ben ZeskindCo-Founder, President, Chief Executive Officer, Director · Since at least Jun 24, 2026
Bob CarpenterCo-founder, Chair Emeritus · Since at least Nov 10, 2026
Brett HallChief Scientific Officer · Since at least Jun 20, 2025
David CaouetteVice President, Corporate Communications · Since at least Oct 29, 2026
Dominic CapassoAssociate General Counsel · Since at least Nov 10, 2026
Doris Perez DiazClinical Trial Manager · Since at least Nov 10, 2026
Grant BogleBoard Member · Since Nov 9, 2026
Harold Eugene BrakewoodChief Business Officer · Since at least Mar 27, 2023
Jason FuntVice President, Translational Genomics · Since at least May 21, 2026
Kevin D. FowlerVice President, Translational Research · Since at least Nov 5, 2026
Leah NeufeldCHIEF PEOPLE OFFICER · Since at least Oct 17, 2022
Loretta SullivanVice President, Medical Affairs and Scientific Development · Since at least Nov 10, 2026
Mallory MoralesSVP Finance, CAO · Since at least Aug 11, 2022
Marty HughesExecutive Director, CMC · Since at least Nov 10, 2026
Nair PraveenVice President, Head of Translational Pharmacology · Since at least Nov 10, 2026
Paula GeorgeSenior Director, Accounting & Operations; Assistant Corporate Controller · Since at least Nov 10, 2026
Peter FeinbergBoard Member · Since at least Jul 29, 2021
Praveen NairVice President, Head of Translational Pharmacology · Nov 4, 2026 – Nov 10, 2026 · Past
Robert J CarpenterDirector · Since at least Jun 13, 2025
Scott BarrettCHIEF MEDICAL OFFICER · Jul 29, 2021 – Feb 15, 2023 · Past
Scott NguyenExecutive Director, IT · Since at least Nov 10, 2026
Stephen SebastianExecutive Director, Corporate Controller · Since at least Nov 10, 2026
Tom SchallBoard Chair · Since at least Nov 10, 2026
Tyler MeadSenior Manager, Financial Reporting and Internal Controls · Since at least Nov 10, 2026
Vinny HayrehVice President, Clinical Development · Since at least May 21, 2026
Will DrewDirector, High Performance Computing · Nov 4, 2026 – Nov 10, 2026 · Past
Zhang JennyExecutive Director, Genomic Data Science · Since at least Nov 10, 2026

Open People

Log in to ask 6ix AI your own questions about Immuneering Corporation.